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Background: Gastroparesis is a condition characterized by epigastric symptoms and
delayed gastric emptying (GE) rate in the absence of any mechanical obstruction.
The condition is challenging in clinical practice by the lack of guidance concerning
diagnosis and management of gastroparesis.
Methods: A Delphi consensus was undertaken by 40 experts from 19 European
countries who conducted a literature summary and voting process on 89 state-
ments. Quality of evidence was evaluated using grading of recommendations
assessment, development, and evaluation criteria. Consensus (defined as ≥80%
agreement) was reached for 25 statements.
Results: The European consensus defined gastroparesis as the presence of symp-
toms associated with delayed GE in the absence of mechanical obstruction. Nausea
and vomiting were identified as cardinal symptoms, with often coexisting post-
prandial distress syndrome symptoms of dyspepsia. The true epidemiology of gas-
troparesis is not known in detail, but diabetes, gastric surgery, certain neurological
and connective tissue diseases, and the use of certain drugs recognized as risk
factors. While the panel agreed that severely impaired gastric motor function is
present in these patients, there was no consensus on underlying pathophysiology.
The panel agreed that an upper endoscopy and a GE test are required for diagnosis.
Only dietary therapy, dopamine‐2 antagonists and 5‐HT4 receptor agonists were
considered appropriate therapies, in addition to nutritional support in case of severe
weight loss. No consensus was reached on the use of proton pump inhibitors, other
classes of antiemetics or prokinetics, neuromodulators, complimentary, psycholog-
ical, or more invasive therapies. Finally, there was consensus that gastroparesis
adversely impacts on quality of life and healthcare costs and that the long‐term
prognosis of gastroparesis depends on the cause.
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Conclusions and Inferences: A multinational group of European experts summa-
rized the current state of consensus on definition, symptom characteristics, path-
ophysiology, diagnosis, and management of gastroparesis.
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Key Summary
Current knowledge
� The epidemiology of gastroparesis is not well known.
� Diagnosis and treatment of gastroparesis is challenging due to uncertainties in definition
and optimal therapeutic approach.
What is new here
� A Delphi panel consisting of 40 experts from 19 European countries established the level of
consensus on 89 statements regarding gastroparesis.
� The statements reaching consensus serve to guide clinicians in recognizing, diagnosing and
treating gastroparesis in clinical practice.
� The statements without consensus identify areas in need of future research.
INTRODUCTION
Gastroparesis is a condition characterized by epigastric symptoms
(nausea, vomiting, postprandial fullness, early satiation, and epigas-
tric pain) and significantly delayed gastric emptying (GE) rate in the
absence of any mechanical obstruction.1,2 Gastroparesis is a
complication of diabetes, especially type 1 diabetes, and may also
occur following upper gastrointestinal tract surgery. Nevertheless, in
the largest subgroup no underlying cause is identified and these
patients are referred to as having idiopathic gastroparesis.1,2
The epidemiology of gastroparesis is unknown, as it requires
procedures such as GE tests to make a firm diagnosis. In clinical
gastroenterology practice, gastroparesis is frequently encountered
and considered one of the more challenging conditions, as there are
uncertainties in terms of definition, symptom spectrum, diagnosis and
optimal therapeutic approach, especially as there is a paucity of in-
terventions with established efficacy.1–4
The aim of this project was to develop a European consensus on
the definition, clinical characteristics, pathophysiological concepts,
diagnosis and management of gastroparesis, with a focus on idio-
pathic gastroparesis. The results of this consensus can offer the
clinician guidance in diagnosing and managing these patients, with
the aim to optimizing outcomes.
METHODS
The European Society for Neurogastroenterology and Motility
(ESNM) initiated a Delphi process, to develop consensus statements
on different aspects of functional dyspepsia (FD) and gastroparesis in
collaboration with other European societies. The Delphi approach,
which combines the principles of evidence‐based medicine, sup-
ported by systematic literature reviews and a voting process, aims to
determine consensus for complex problems in medicine for which
evidence from controlled trials is lacking.5
The principal steps in the process were: (1) selection of a
working group of eight ESNM members with expertise in FD and
gastroparesis and/or Delphi consensus processes; (2) selection of a
European Consensus Group consisting of experts in FD and gastro-
paresis from different European countries, recruited through the
ESNM board and through United European Gastroenterology (UEG)
Federation Sister Societies; (3) drafting of statements allowing to
evaluate the current knowledge on gastroparesis; (4) systematic
literature reviews to identify evidence to support each statement; (5)
two rounds of repeated voting of the statements and voting dis-
cussion until a stable level of consensus voting was reached; and (6)
grading of the strength using accepted criteria.
For the Consensus Group, ESNM board members nominated
experts from their respective national societies for participation, and
the UEG Sister Societies (European Association for Gastroenterology,
Endoscopy and Nutrition, European Helicobacter and Microbiota
Study Group and the European Society for Primary Care Gastroen-
terology) nominated additional experts. A total of 40 experts from 19
European countries agreed to participate. Members had a back-
ground of expertise in gastroenterology, general practice, gastric
physiology, or gastrointestinal motility. All members submitted a
conflict of interest statement by December 2018. The ESNM FD
guideline was finalized and published separately.6
The eight‐member Core Group drafted and finalized a list of 65
statements covering several aspects of gastroparesis. The finalized
list was evaluated in a first voting round by all members in the second
quarter of 2019, where each member indicated the degree of
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agreement for the statement using a 6‐point Likert scale (Table 1).
Participants were blinded to the votes of other participants and also
gave feedback on clarity of the statement and made suggestions for
adapting or splitting the statements into two or more questions, or
for adding additional statements on a given topic. The Core Group
adjusted the statement list, generating a total of 91 statements, and
subdivided the Guideline Group members into 12 Working Groups
with 3–4 members each. Each Working Group was allocated state-
ments for which they needed to conduct a systematic literature
search using several relevant keywords and provide narrative sub-
stantiation of the statements. The literature review and references
were made available on a share‐point server, accessible to all mem-
bers. This was finalized by the summer of 2019, followed by a voting
round in which each statement was presented with the evidence
summary, and each member indicated the degree of agreement for
the statement using a 6‐point Likert scale (Table 1). Participants were
blinded to the votes of other participants. Available members of the
Guideline Group met in September 2019 at the ESNM meeting in
Lisbon and in October 2019 at the UEG week in Barcelona, to discuss
statements and voting outcomes. A final voting round was conducted
after these meetings, finalized by early 2020 and focusing on state-
ments that were adapted based on the evaluation at the ESNM
meeting. Throughout the process, all votes were mutually anonymous
and blinded.
Consensus was defined as when at least 80% of the Consensus
Group agreed (A+ or A) with a statement. The strength of evidence
for each statement was scored using the GRADE system (Table 2).7
After the final voting round, the manuscript was drafted and circu-
lated for final approval by the participants. The references cited in
this chapter are only a selection of the articles reviewed in each area,
chosen to clarify the discussion. A final meeting planned in October
2020 was canceled because of the COVID‐19 pandemic.
RESULTS
1. Definitions and symptom descriptors
1.1 Gastroparesis refers to a symptom or set of symptoms that is
(are) associated with delayed GE in the absence of mechan-
ical obstruction.
STATEMENT ENDORSED, overall agreement 100%: A+ 60%,
A 40%, A− 0%, D− 0%, D 0%, D+ 0%. GRADE A
1.2 Gastroparesis refers to a symptom or set of symptoms that is
(are) associated with severely disturbed gastric motor func-
tion in the absence of mechanical obstruction.
STATEMENT ENDORSED, overall agreement 85%: A+ 48%,
A 38%, A− 13%, D− 3%, D 0%, D+ 0%. GRADE B
1.3 Nausea and vomiting are cardinal symptoms in gastroparesis.
STATEMENT ENDORSED, overall agreement 95%: A+ 68%,
A 28%, A− 5%, D− 0%, D 0%, D+ 0%. GRADE B
1.4 Dyspeptic symptoms such as postprandial fullness, early
satiation, epigastric pain, as well as bloating in the upper
abdomen and belching are often present in gastroparesis
patients.
STATEMENT ENDORSED, overall agreement 95%: A+ 60%,
A 35%, A− 5%, D− 0%, D 0%, D+ 0%. GRADE B
TAB L E 1 6‐Point Likert scale
Point Description
A+ Agree strongly
A Agree with minor reservation
A− Agree with major reservation
D− Disagree with major reservation
D Disagree with minor reservation
D+ Disagree strongly
TAB L E 2 Grading of recommendations assessment, development and evaluation system9
Code Quality of evidence Definition
A High Further research is very unlikely to change our confidence in the estimate of effect
� Several high‐quality studies with consistent results
� In special cases: one large, high‐quality multicenter trial
B Moderate Further research is likely to have an important impact on our confidence in the estimate of
effect and may change the estimate
� One high‐quality study
� Several studies with some limitations
C Low Further research is very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate
� One or more studies with severe limitations
D Very low Any estimate of effect is very uncertain
� Expert opinion
� No direct research evidence
� One or more studies with very severe limitations
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1.5 Symptoms in gastroparesis patients overlap mainly with PDS
and less with EPS symptoms of FD.
STATEMENT ENDORSED, overall agreement 90%: A+ 45%,
A 45%, A− 8%, D− 0%, D 3%, D+ 0%. GRADE B
The presence of symptomatic delayed GE is mandatory for a
patient to be diagnosed with gastroparesis.1–4 The delay in GE rate
should be based on a well‐established reference range in healthy,
asymptomatic controls (usually the 97.5th percentile, reflecting a
95% normal reference range). Asymptomatic delayed GE may be
present especially in diabetic patients.8 However, it has been pro-
posed not to include asymptomatic subjects in the diagnosis of gas-
troparesis.4 Mechanical obstruction, which can also lead to a delayed
GE, should be excluded.1–4
A variable range of symptoms may be present in patients with
gastroparesis, including nausea, vomiting, early satiety, bloating,
postprandial fullness, abdominal pain/discomfort, and anorexia.4,9–12
A systematic review and meta‐analysis, which included only studies
with a high‐quality emptying test showed significant associations
between the presence of delayed GE and symptoms of nausea,
vomiting, early satiety, postprandial fullness and epigastric pain.9
Other studies also confirmed that gastroparesis symptoms have
considerable overlap with FD defined by the Rome IV criteria.4,10,11
A problem of this definition is that the association between
delayed GE and symptoms may suggest that delayed GE is directly
causing the symptoms. However, this conclusion should be consid-
ered with caution.4 Symptoms occurring in subjects with delayed GE
may also be associated with other types of gastric sensorimotor
dysfunction, such as impaired gastric accommodation, hypersensi-
tivity to gastric distention and uncoordinated intense motor activity
in proximal small bowel.12–14
Gastroparesis is a chronic condition and symptoms have to be
present for some time before a diagnosis is triggered, and a time-
frame of at least 3 months was proposed.15 Nausea is the most
common symptom in gastroparesis, affecting more than 95%, and has
been associated with the severity of delay in emptying.4,9,10,16
Vomiting is associated with nausea and with more severe delay in
GE.8,9,17 The recently published ESNM FD consensus identified early
satiation, postprandial fullness and epigastric pain or burning as
cardinal FD symptoms.6 Nausea and vomiting are not cardinal
symptoms of FD, thus allowing the symptom profiles of both entities
to be distinguished.4,18,19 Based on these observations, nausea and
vomiting are considered cardinal symptoms of gastroparesis by this
panel, providing a different symptom basis for both conditions.1,4,18
Nevertheless, the symptoms of gastroparesis largely overlap
with those of FD. A US study of 243 patients with idiopathic gas-
troparesis showed that 86% of patients fulfilled the ROME III criteria
for FD, especially postprandial distress syndrome (PDS), which was
present in 91%, compared to epigastric pain syndrome (EPS) in
1.2%.11 Another study showed that of 357 patients referred for
gastroparesis symptoms overlapping FD was found in 90.8%, espe-
cially PDS, which was present in 88.3% and EPS in 59.8%.20 A number
of studies have reported the presence of pain in a large subset of
gastroparesis patients, although some of these studies included pa-
tients taking opioids, which is a major confounder.21,22 In studies that
exclude patients on opioids, pain is less prevalent, and it is also
inconsistently correlated with GE delay.4,8–13,16,17,20 Bloating is a
common symptom of functional digestive disorders including FD and
IBS, but its prevalence is high in gastroparesis patients.9,10,12,16,17
2. Epidemiology and risk factors
2.1 The epidemiology of gastroparesis is not established, mainly
because it requires GE testing which has not been done at
the population level.
STATEMENT ENDORSED, overall agreement 93%: A+ 40%,
A 53%, A− 8%, D− 0%, D 0%, D+ 0%. GRADE B
2.2 Diabetes is a risk factor for development of gastroparesis.
STATEMENT ENDORSED, overall agreement 100%: A+ 85%,
A 12%, A− 3%, D− 0%, D 0%, D+ 0%. GRADE A
2.3 Acute gastrointestinal infection is a risk factor for develop-
ment of gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 59%: A+
18%, A 40%, A− 33%, D− 3%, D 5%, D+ 3%. GRADE B
2.4 Partial gastric resection/vagotomy, bariatric surgery, antire-
flux surgery are risk factors for development of gastroparesis
STATEMENT ENDORSED, overall agreement 85%: A+ 40%,
A 45%, A− 13%, D− 0%, D 3%, D+ 0%. GRADE B
2.5 Hypothyroidism is a risk factor for development of gastro-
paresis.
STATEMENT NOT ENDORSED, overall agreement 56%: A+
23%, A 33%, A− 28%, D− 10%, D 8%, D+ 0%. GRADE C
2.6 Some neurological disorders (e.g., Parkinson's disease, mul-
tiple sclerosis, amyloid neuropathy) are associated with
increased risk for gastroparesis.
STATEMENT ENDORSED, overall agreement 90%: A+ 33%,
A 55%, A− 10%, D− 0%, D 3%, D+ 0%. GRADE B
2.7 Some connective tissue diseases are associated with
increased risk for gastroparesis.
STATEMENT ENDORSED, overall agreement 85%: A+ 43%,
A 43%, A− 13%, D− 3%, D 0%, D+ 0%. GRADE B
2.8 Some drugs (e.g., opioids) are associated with increased risk
for gastroparesis.
STATEMENT ENDORSED, overall agreement 100%: A+ 63%,
A 38%, A− 0%, D− 0%, D 0%, D+ 0%. GRADE A
As a diagnosis of gastroparesis requires symptoms, an objective
demonstration of delayed GE and absence of a mechanical obstruc-
tion,1–4 no population‐based studies have addressed its prevalence.
Currently, analyses of diagnostic records and procedures suggest a
low prevalence of formally diagnosed gastroparesis. In Olmsted
county, based on hospital records and population adjustments, the
estimated incidence was 6.3 (4.9–7.7) per 100,000 person‐years. The
age‐adjusted prevalence of gastroparesis per 100,000 persons was
24.2 (15.7–32.6), with a female predominance (82% female).23 An
analysis of the UK Clinical Practice Research Datalink (CPRD) data-
base generated standardized prevalence of 13.8 (95% confidence
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interval [CI]: 12.6–15.1) per 100,000 persons in 2016, and stan-
dardized incidence of 1.9 (95% CI: 1.4–2.3) per 100,000 person‐years
in 2016, with female predominance (64% female).24
In these cohorts, the idiopathic subgroup is the largest, but a high
prevalence of gastroparesis is found among diabetic patients, with 25
and 38% of patients identified in the respective studies.23,24 Gastro-
paresis occurs more frequently in type 1 diabetes compared to type
2.2,4 In a population‐based, historical cohort study, the cumulative
proportions developing gastroparesis over a 10‐year time period were
5.2% in type 1DM, 1.0% in type 2DM, compared to 0.2% in controls.25
There is limited evidence suggesting that (viral) gastrointestinal
infections may cause postinfectious gastroparesis. In a single center
cohort, 52 out of 143 patients diagnosed with gastroparesis, 52 were
idiopathic in origin, with 12 of them considered to be consistent with
a postviral etiology.26 In the NIDDK cohort, of 243 subjects with
idiopathic gastroparesis, 19% reported a history suggestive of in-
fectious etiology.17 Small studies reported viral presence in the
mucosa of patients with gastroparesis.27,28
Postsurgical gastroparesis is well established and may occur
after gastric surgery, antireflux surgery, lung transplant, pan-
creaticoduodenectomy and esophagectomy.29,30 Hypothyroidism is
more frequent in gastroparesis compared to the general population
(14% of patients vs. 8.2% in controls).31 Several neurological and
systemic disorders have also been linked to gastroparesis, including
Parkinson's disease, systemic sclerosis, and so on.23,31–33
Several drugs can retard GE, of which opioids have the greatest
impact.1,4 Opioids may induce or worsen gastroparesis and its
symptoms, and it has been argued that patients on opioids should not
be considered as gastroparesis unless the diagnosis is confirmed off
opioids.1,4,21,34
3. Impact of gastroparesis
3.1 Gastroparesis is a major source of healthcare costs.
STATEMENT ENDORSED, overall agreement 85%: A+ 35%,
A 50%, A− 13%, D− 0%, D 3%, D+ 0%. GRADE A
3.2 Gastroparesis is associated with decreased life expectancy.
STATEMENT NOT ENDORSED, overall agreement 18%: A+
5%, A 13%, A− 38%, D− 18%, D 23%, D+ 3%. GRADE B
3.3 Gastroparesis is a major source of self‐costs to patients.
STATEMENT NOT ENDORSED, overall agreement 65%: A+
18%, A 48%, A− 25%, D− 3%, D 5%, D+ 0%. GRADE B
3.4 Gastroparesis is an important source of loss of work pro-
ductivity.
STATEMENT NOT ENDORSED, overall agreement 78%: A+
28%, A 50%, A− 20%, D− 0%, D 3%, D+ 0%. GRADE B
3.5 Gastroparesis is associated with a significant decrease in
quality of life.
STATEMENT ENDORSED, overall agreement 93%: A+
68%, A 25%, A− 8%, D− 0%, D 0%, D+ 0%. GRADE A
3.6 Gastroparesis is associated with psychosocial comorbidities
such as anxiety and depression.
STATEMENT ENDORSED, overall agreement 83%: A+ 33%,
A 50%, A− 15%, D− 3%, D 0%, D+ 0%. GRADE A
3.7 Weight loss can be a consequence of gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 70%: A+
40%, A 30%, A− 28%, D− 3%, D 0%, D+ 0%. GRADE B
3.8 In case of weight loss, eating disorders must be ruled out.
STATEMENT ENDORSED, overall agreement 98%: A+ 40%,
A 58%, A− 3%, D− 0%, D 0%, D+ 0%. GRADE B
3.9 Healthcare consulting behavior in gastroparesis is driven by
symptom severity and impact.
STATEMENT NOT ENDORSED, overall agreement 78%: A+
20%, A 58%, A− 18%, D− 3%, D 3%, D+ 0%. GRADE B
3.10 Healthcare consulting behavior in gastroparesis is driven by
psychosocial comorbidity.
STATEMENT NOT ENDORSED, overall agreement 40%: A+
15%, A 25%, A− 38%, D− 8%, D 15%, D+ 0%. GRADE B
3.11 Healthcare consulting behavior in gastroparesis is driven by
access to the healthcare system.
STATEMENT NOT ENDORSED, overall agreement 54%: A+
10%, A 43%, A− 35%, D− 8%, D 5%, D+ 0%. GRADE B
Only a few studies, mainly from the United States, have inves-
tigated the impact of gastroparesis on healthcare costs. Based on the
National Inpatient Sample Database, which is designed to include
approximately 95% of the US population, a remarkable 300% in-
crease in gastroparesis‐related admissions occurred in the United
States between 1997 and 2013, with a decrease in average length of
stay but an increase in the cost of each hospitalization with time.35
Over the same time period, emergency department visits for gas-
troparesis more than doubled, and this was also associated with
substantial healthcare costs.36
In a population‐based study in Olmsted county, overall sur-
vival of subjects diagnosed with gastroparesis was significantly
lower than the age‐ and sex‐specific expected survival computed
for the reference population, and a higher mortality was seen in
diabetic versus idiopathic gastroparesis.23 In the UK CPRD data-
base study, mortality rates were also higher in diabetic compared
to idiopathic gastroparesis patients.24 However, in these studies
the excess mortality was largely driven by cardiovascular
comorbidity.
No data are available on self‐cost to gastroparesis patients, but
they may incur both direct and indirect costs for use of OTC medi-
cations (antiemetics, antacids, and H2 receptor antagonists), alter-
native therapies, medical consultations, and cofinanced treatments,
as well as the cost of some dietary adjustments and nutritional
support, which is often not reimbursed.
In a small US gastroparesis patient cohort, the majority of pa-
tients surveyed (54%) was not employed and considered disabled.37
Employment rates are even lower in those on opioids.38 In a survey of
almost 500 gastroparesis patients, the symptoms reduced daily ac-
tivities in 67.5% and lowered annual income in 28.5%; 11% were
disabled due to gastroparesis symptoms.39 Quality of life was
significantly decreased in this cohort. Also, in a large online survey of
over 1400 self‐reported gastroparesis patients, quality of life as
measured by the 36‐item short‐form health survey was decreased,
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mainly on the physical health component, and this was negatively
correlated with increased symptom severity, especially nausea, early
satiety, and abdominal pain.40
In a study of 299 gastroparesis patients enrolled from US referral
centers, anxiety and depression scores correlated with the severity of
gastroparesis symptoms but did not differ between diabetic and
idiopathic gastroparesis and did not correlate with the delay in GE
rate.41 In a systematic review, based on three studies in gastroparesis
(n = 378) combined anxiety/depression was present in 24% of pa-
tients, severe anxiety in 12.4%, depression in 23%, and somatization
in 50%.42
Although it is often assumed that gastroparesis may lead to
weight loss, this is not substantiated in the literature. In large cohorts
of patients with dyspeptic symptoms, delayed GE was not associated
with weight loss.8,43 Gastroparesis may affect adolescent and young
patients. When accompanied by weight loss, an eating disorder
should be excluded, especially since delayed GE is a feature of
anorexia nervosa.44,45
Healthcare consulting in gastroparesis is likely driven by symp-
tom severity and impact, but no data are available from the literature.
Moreover, it is not known whether healthcare consulting is driven by
psychosocial comorbidity, although this seems plausible given its
correlation with symptom severity.41 A study in the United States
showed regional differences in healthcare assistance in gastroparesis
patients, with admissions rates independently predicted by high
overall hospitalizations within a state, suggesting that access to
healthcare is a factor determining healthcare consulting.46
4. Pathophysiology of gastroparesis
4.1 Delay in GE underlies symptom generation in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 28%: A+
10%, A 18%, A− 48%, D− 13%, D 10%, D+ 0%. GRADE B
4.2 Impaired gastric accommodation contributes to symptom
generation in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 75%: A+
20%, A 55%, A− 20%, D− 3%, D 3%, D+ 0%. GRADE B
4.3 Hypersensitivity to gastric distention contributes to symp-
tom generation in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 73%: A+
18%, A 55%, A− 20%, D− 5%, D 3%, D+ 0%. GRADE B
4.4 Duodenal mucosal alterations (low grade inflammation,
impaired permeability) are not implicated as pathophysio-
logical mechanisms in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 58%: A+
10%, A 48%, A− 25%, D− 10%, D 8%, D+ 0%. GRADE C
4.5 Loss of interstitial cells of Cajal is a pathophysiological
mechanism in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 60%: A+
10%, A 50%, A− 33%, D− 0%, D 8%, D+ 0%. GRADE B
4.6 Loss of enteric nerves is a pathophysiological mechanism in
gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 65%: A+
5%, A 60%, A− 30%, D− 0%, D 5%, D+ 0%. GRADE B
4.7 Primary changes in gastric smooth muscle are a patho-
physiological mechanism in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 53%: A+
8%, A 45%, A− 38%, D− 5%, D 5%, D+ 0%. GRADE B
4.8 Loss of agus nerve function is a pathophysiological mecha-
nism in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 68%: A+
8%, A 60%, A− 30%, D− 3%, D 0%, D+ 0%. GRADE B
4.9 Helicobacter pylori infection is not a pathophysiological
mechanism in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 60%: A+
18%, A 43%, A− 23%, D− 3%, D 13%, D+ 3%. GRADE B
4.10 Altered gastric acid secretion is not a pathophysiological
mechanism in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 78%: A+
23%, A 55%, A− 15%, D− 5%, D 3%, D+ 0%. GRADE C
4.11 Altered release of peptide hormones is not a pathophysio-
logical mechanism in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 60%: A+
5%, A 55%, A‐ 23%, D‐ 8%, D 8%, D+ 3%. GRADE C
4.12 Increased sensitivity to duodenal luminal content is not a
pathophysiological mechanism in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 70%: A+
3%, A 68%, A‐ 18%, D‐ 8%, D 5%, D+ 0%. GRADE C
4.13 Altered duodenal microbiota composition is not a patho-
physiological mechanism in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 59%: A+
10%, A 48%, A− 25%, D− 10%, D 5%, D+ 3%. GRADE C
4.14 Anxiety is a pathophysiological factor in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 43%: A+
10%, A 33%, A− 28%, D− 15%, D 13%, D+ 3%. GRADE B
4.15 Depression is a pathophysiological factor in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 43%: A+
8%, A 35%, A− 28%, D− 13%, D 15%, D+ 3%. GRADE B
4.16 Disordered processing of incoming signals from the
gastroduodenal region is a pathophysiological mechanism in
gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 58%: A+
5%, A 53%, A− 25%, D− 10%, D 5%, D+ 3%. GRADE B
4.17 Genetic factors determine susceptibility to gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 55%: A+
0%, A 55%, A− 30%, D− 8%, D 8%, D+ 0%. GRADE C
Symptoms of gastroparesis, either alone or collectively, have
proven tobepoor predictors of the rate ofGEor response to prokinetic
agents. However, a number of observations showed a tendency for
more severe symptom burden with more severely delayed emptying,
but the association is inconsistent.1–4,8–13,16,17,20,21,32 A systematic
review and meta‐analysis, including only studies with a high‐quality
emptying test showed significant associations between the presence
of delayed GE and symptoms of nausea, vomiting, early satiety, post-
prandial fullness, and epigastric pain.9 However, the relationship
between symptom severity and emptying delay remains poor.
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In idiopathic gastroparesis, barostat studies demonstrated that
43% of patients had impaired accommodation, associated with a
higher prevalence of weight loss and early satiety, 29% of patients
had hypersensitivity to gastric distension, associated with higher
rates of early satiety, epigastric pain, and weight loss.12 In diabetic
gastroparesis, gastric accommodation to a meal and sensory
thresholds for discomfort were lower compared to healthy con-
trols.13 Impaired duodenal mucosal integrity, with mucosal infiltra-
tion with eosinophils and mast cells, has been reported as a putative
pathophysiological mechanism in FD but studies in gastroparesis
seem to be lacking.47
Histopathological studies in an animal model of type 1 diabetes
and transmural biopsy specimens from gastroparesis patients
showed decreased density of interstitial cells of Cajal, possibly due to
switch from anti‐inflammatory M2 macrophages to pro‐inflammatory
M1 macrophages.48,49 Conflicting data exist on a possible decrease of
electrically coupled platelet‐derived growth factor receptor α‐fibro-
blast‐like cells in gastroparesis.50,51
In small patient cohort studies, fibrotic and inflammatory
changes to gastric smooth muscle were reported in diabetic gastro-
paresis patients, but this was not confirmed in the larger NIDDK
consortium cohort.48,49,52
In a study which evaluated heart‐rate variability responses in 41
gastroparesis patients, diabetic gastroparesis was more frequently
associated with signs of vagal dysfunction than idiopathic gastro-
paresis.53 In a large study of 242 patients, there were signs of both
sympathetic and parasympathetic dysfunction, the latter associated
with more severe symptoms and more delayed GE.54
Few studies have evaluated the relationship between H. pylori
status and GE rate, but no consistent correlation was found.55–57 No
studies evaluated gastric acid secretion, duodenal sensitivity to acid
or lipids or duodenal microbiota composition in gastroparesis. There
is also no consistent proof of altered release of gut peptides
contributing to gastroparesis pathophysiology.58
Several authors have reported higher degrees of anxiety and
depression in gastroparesis patients. In those studies, anxiety and
depression scoreswere related to gastroparesis symptom severity and
hospitalization rates but not to disease etiology and GE rates.16,17,21,31
Both in idiopathic and in diabetic gastroparesis, hypersensitivity
to gastric distension is present and, in the former group, is asso-
ciated with the symptom pattern and severity (higher rates of early
satiety, epigastric pain, and weight loss).12,13 As gastric compliance
is not altered in these patients, the pathophysiology is likely to
involve altered processing of incoming signals in the central nervous
system. One study using evoked potentials showed altered pro-
cessing of esophageal electrical stimulation signals in the brain in
patients with diabetic neuropathy, and this was related to upper
gastrointestinal symptom severity and quality of life impact.59
An fMRI study showed altered connectivity of the insula and a
tendency towards decreased insula gray matter volume in gastro-
paresis patients.60
Only a few studies have evaluated genetic factors that predispose
for the development of gastroparesis. A long repeat polymorphism in
the heme oxygenase (HO1) has been associated with worse outcomes
in several diseases, including gastroparesis, and the presence of
longer polyGT repeats in the HMOX1 promoter results in lower
transcriptional activity compared to shorter repeats.61
5. Diagnosis
5.1 Upper gastrointestinal endoscopy is mandatory for estab-
lishing a diagnosis of gastroparesis.
STATEMENT ENDORSED, overall agreement 93%: A+ 75%,
A 18%, A− 8%, D− 0%, D 0%, D+ 0%. GRADE A
5.2 The presence of food in fasting state during endoscopy is
diagnostic for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 40%: A+
10%, A 30%, A− 30%, D− 10%, D 15%, D+ 5%. GRADE B
5.3 An abnormal GE test is mandatory for establishing a diag-
nosis of gastroparesis.
STATEMENT ENDORSED, overall agreement 95%: A+ 80%,
A 15%, A− 3%, D− 0%, D 3%, D+ 0%. GRADE A
5.4 Scintigraphic GE assessment is a valid test for diagnosing
gastroparesis.
STATEMENT ENDORSED, overall agreement 98%: A+ 88%,
A 10%, A− 3%, D− 0%, D 3%, D+ 0%. GRADE A
5.5 Breath test assessment is a valid test for diagnosing gastro-
paresis.
STATEMENT ENDORSED, overall agreement 95%: A+ 60%,
A 35%, A− 0%, D− 3%, D 3%, D+ 0%. GRADE A
5.6 Wireless motility capsule assessment is a valid test for
diagnosing gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 33%: A+
8%, A 25%, A− 48%, D− 5%, D 15%, D+ 0%. GRADE B
5.7 Gastric ultrasound assessment is a valid test for diagnosing
gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 18%: A+
5%, A 13%, A− 48%, D− 5%, D 28%, D+ 3%. GRADE B
5.8 Small bowel obstruction can be ruled out in gastroparesis
through imaging.
STATEMENT ENDORSED, overall agreement 88%: A+ 25%,
A 63%, A− 10%, D− 0%, D 3%, D+ 0%. GRADE B
Esophagogastroduodenoscopy (EGD), is a prerequisite for the
diagnosis of gastroparesis to be made. Most guidelines dictate that an
EGD should be performed before motility testing is considered in
patients with upper abdominal symptoms not responding to first‐line
therapy to exclude gastric outlet obstruction.1,2,19
Food retention in the stomach as seen during EGD after an over-
night fast has been used as a probable sign of gastroparesis in epide-
miological studies, even in the presence of a normalGE test.23Only one
retrospective analysis study specifically addressed the relationship
between GE and food retention, suggesting that gastric food retention
at endoscopy could be amoderately specific sign for gastroparesis, but
with poor sensitivity.62
The definition of gastroparesis implies objective delayed GE in
the absence of mechanical obstruction. To date, GE scintigraphy of a
SCHOL ET AL. - 293
solid‐phase meal is considered the gold standard, and by consensus,
the test is performed using a 99mTechnetium‐labeled standardized
low‐fat, egg meal with imaging at 0, 1, 2, and 4 h after meal inges-
tion.63 The scintigraphic emptying test is fairly reproducible between
repeated studies in patients with upper gastrointestinal symptoms,
with a concordance correlation coefficient of 0.54 for GE assessment
at 4 h, and of 0.79 for GE half time.64 GE breath test (GEBT) is an
FDA‐approved method for the evaluation of GE. GEBT incorporates a
stable isotope, 13C, in a substrate such as octanoic acid, acetate or
spirulina platensis. This non‐invasive method is easy to perform, with
similar or lower cost to scintigraphy, and does not involve exposing
patients to ionizing radiation. Previous studies have shown high
correlation (0.73–0.95) between scintigraphy and breath test GE
times.65
The wireless motility capsule (WMC) is an FDA‐approved device
for the evaluation of GE. A systematic review from 2013 that
included seven studies found that for the diagnosis of gastroparesis,
as compared with gastric scintigraphy, WMC had a sensitivity of
59%–86% and specificity of 64%–81%.66 The pitfall with WMC is
that it is an indigestible solid and, therefore, it empties from the
stomach in response to phase 3 migrating motor complexes rather
than with the test meal. A further disadvantage is that WMC is
relatively expensive and its availability across different centers is
limited.
Gastric ultrasonography has been used to assess antral wall
motion, patterns of transpyloric flow, and GE based on changes in the
cross‐sectional area or diameter of the gastric antrum. Gastric ul-
trasonography is noninvasive, safe, cheap, widely available, allows for
bedside monitoring, does not expose the patient to ionizing radiation
which is restricted particularly in children and pregnant women, and
shows reasonably good interobserver agreement in the evaluation of
liquid GE.66 However, ultrasonography is unable to distinguish be-
tween the solid and liquid components of a meal and therefore is
unsuitable to assess emptying of solids. Ultrasonography also re-
quires an experienced technician, is user dependent, may be influ-
enced by the presence of intragastric air or posture and is generally
considered impractical for prolonged observations.67
When small bowel obstruction is suspected, patients generally
undergo abdominal radiography which is widely available, inexpen-
sive and has a reported accuracy of 50%–86%. Where small bowel
obstruction is strongly suspected, CT scanning is the most accurate
examination.68
6. Treatment
6.1 Dietary adjustments are useful for managing gastroparesis
patients.
STATEMENT ENDORSED, overall agreement 85%: A+ 35%,
A 50%, A− 15%, D− 0%, D 0%, D+ 0%. GRADE B
6.2 Proton pump inhibitor (PPI) therapy is the most appropriate
first line therapy for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 0%: A+
0%, A 0%, A− 18%, D− 13%, D 55%, D+ 15%. GRADE C
6.3 PPI therapy is effective in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 10%: A+
0%, A 10%, A− 15%, D− 23%, D 48%, D+ 5%. GRADE C
6.4 PPI therapy is only effective for associated reflux symptoms
in gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 70%: A+
15%, A 55%, A− 25%, D− 3%, D 3%, D+ 0%. GRADE C
6.5 Antiemetic (anti‐“nauseant”) therapy is the most appro-
priate first line therapy for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 43%: A+
5%, A 38%, A− 33%, D− 10%, D 15%, D+ 0%. GRADE B
6.6 Antiemetic (anti‐“nauseant”) therapy is effective for gas-
troparesis.
STATEMENT NOT ENDORSED, overall agreement 48%: A+
8, A 40%, A− 45%, D− 3%, D 5%, D+ 0%. GRADE B
6.7 Dopamine‐2 antagonists are effective for gastroparesis.
STATEMENT ENDORSED, overall agreement 86%: A+ 23%,
A 63%, A− 15%, D− 0%, D 0%, D+ 0%. GRADE B
6.8 5‐HT3 antagonists are effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 63%: A+
5%, A 58%, A− 33%, D− 5%, D 0%, D+ 0%. GRADE B
6.9 NK1 antagonists are effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 40%: A+
5%, A 35%, A− 48%, D− 3%, D 10%, D+ 0%. GRADE B
6.10 Prokinetic therapy is the most appropriate first line therapy
for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 78%: A+
38%, A 40%, A− 15%, D− 0%, D 8%, D+ 0%. GRADE B
6.11 Prokinetic therapy is effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 75%: A+
18%, A 58%, A− 23%, D− 0%, D 3%, D+ 0%. GRADE B
6.12 The efficacy of prokinetics is not related to their enhance-
ment of GE rate.
STATEMENT NOT ENDORSED, overall agreement 55%: A+
10%, A 45%, A− 35%, D− 5%, D 5%, D+ 0%. GRADE B
6.13 Itopride is effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 35%: A+
5%, A 30%, A− 23%, D− 23%, D 20%, D+ 0%. GRADE B.
6.14 5‐HT4 agonists are effective for gastroparesis.
STATEMENT ENDORSED, overall agreement 85%: A+ 18%,
A 68%, A− 15%, D− 0%, D 0%, D+ 0%. GRADE B
6.15 Motilin‐receptor agonists are effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 58%: A+
10%, A 48%, A− 40%, D− 0%, D 0%, D+ 3%. GRADE B
6.16 Ghrelin‐receptor agonists are effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 40%: A+
8%, A 33%, A− 53%, D− 3%, D 3%, D+ 3%. GRADE B
6.17 Tricyclic antidepressants are effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 8%: A+
3%, A 5%, A− 25%, D− 23%, D 40%, D+ 5%. GRADE B
6.18 Tricyclic antidepressants are not effective for gastro-
paresis.
294 - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
STATEMENT NOT ENDORSED, overall agreement 65%: A+
8%, A 53%, A− 15%, D− 13%, D 13%, D+ 0%. GRADE B
6.19 SSRI are effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 10%: A+
0%, A 10%, A− 18%, D− 20%, D 50%, D+ 3%. GRADE C
6.20 SSRI are not effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 63%: A+
10%, A 53%, A− 13%, D− 13%, D 13%, D+ 0%. GRADE C
6.21 SNRI are effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 0%: A+
0%, A 0%, A− 13%, D− 30%, D 55%, D+ 3%. GRADE C
6.22 SNRI are not effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 63%: A+
10%, A 53%, A− 25%, D− 5%, D 8%, D+ 0%. GRADE C
6.23 Mirtazapine is effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 35%: A+
5%, A 30%, A− 50%, D− 5%, D 10%, D+ 0%. GRADE B
6.24 5‐HT1A agonists (tandospirone, buspirone, ….) are effective
for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 15%: A+
0%, A 15%, A− 20%, D− 30%, D 33%, D+ 3%. GRADE C
6.25 5‐HT1A agonists are not effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 40%: A+
5%, A 35%, A− 33%, D− 5%, D 23%, D+ 0%. GRADE C
6.26 Gastric electrical stimulation (GES) is effective for gastro-
paresis.
STATEMENT NOT ENDORSED, overall agreement 38%: A+
15%, A 23%, A− 38%, D− 15%, D 10%, D+ 0%. GRADE B
6.27 Pyloric botulinum toxin injection is effective for gastro-
paresis.
STATEMENT NOT ENDORSED, overall agreement 13%: A+
0%, A 13%, A− 38%, D− 20%, D 25%, D+ 5%. GRADE B
6.28 Pyloric myotomy is effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 28%: A+
5%, A 23%, A− 43%, D− 10%, D 20%, D+ 0%. GRADE B
6.29 Partial or subtotal gastrectomy is effective for gastro-
paresis.
STATEMENT NOT ENDORSED, overall agreement 18%: A+
3%, A 15%, A− 38%, D− 8%, D 33%, D+ 5%. GRADE B
6.30 Surgical or pyloric targeting therapies for gastroparesis may
induce dumping syndrome.
STATEMENT NOT ENDORSED, overall agreement 35%: A+
5%, A 30%, A− 40%, D− 8%, D 18%, D+ 0%. GRADE B
6.31 H. Pylori‐infected gastroparesis patients should receive
eradication therapy.
STATEMENT NOT ENDORSED, overall agreement 5%: A+
20%, A 55%, A− 18%, D− 0%, D 8%, D+ 0%. GRADE B
6.32 Herbal therapies are effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 10%: A+
0%, A 10%, A− 45%, D− 20%, D 23%, D+ 3%. GRADE B
6.33 Herbal therapies are not effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 23%: A+
3%, A 20%, A− 23%, D− 38%, D 15%, D+ 3%. GRADE B
6.34 Iberogast (STW‐5) is effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 20%: A+
8%, A 13%, A− 33%, D− 13%, D 35%, D+ 0%. GRADE B
6.35 Hypnotherapy is effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 8%: A+
0%, A 8%, A− 20%, D− 25%, D 43%, D+ 5%. GRADE B
6.36 Cognitive behavioral therapy is effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 15%: A+
0%, A 15%, A− 23%, D− 18%, D 40%, D+ 5%. GRADE B
6.37 Acupuncture is effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 3%: A+
0%, A 3%, A− 43%, D− 5%, D 45%, D+ 5%. GRADE B
6.38 Mindfulness is effective for gastroparesis.
STATEMENT NOT ENDORSED, overall agreement 13%: A+
0%, A 13%, A− 10%, D− 25%, D 48%, D+ 5%. GRADE B
6.39 In case of severe weight loss or intractable vomiting,
nutritional support may be needed in the form of enteral or
parenteral nutrition.
STATEMENT ENDORSED, overall agreement 98%: A+ 53%,
A 45%, A− 3%, D− 0%, D 0%, D+ 0%. GRADE B
A diet composed of small particle size reduces gastroparesis and
reflux symptoms in patients with diabetic gastroparesis.69 In addition,
gastroparesis carries an increased risk for a diet deficient in calories,
which can be corrected by nutritional support and engagement with
dieticians.17
The efficacy of PPIs in gastroparesis has not been addressed in
controlled trials. However, PPI intake is high in gastroparesis patients
(70% or more) and more than 50% have an overlapping GERD
diagnosis.17,70 It has been suggested that the coexisting GERD rather
than gastroparesis is the explanation for the PPI intake.
While they are recommended as first line symptomatic treat-
ment, there are no formal studies establishing efficacy of tradi-
tional antiemetic agents in the treatment of nausea and vomiting
associated with gastroparesis.71 In the United States, metoclopra-
mide, a dopamine‐2 receptor antagonist, is approved for the
treatment of gastroparesis. However, it carries a black box warn-
ing, as it is generally not well‐tolerated and chronic use (>12
weeks) may lead to extrapyramidal side effects and potential
irreversible tardive dyskinesia, which has been reported in a small
percentage of cases.71 In a phase 2, randomized controlled trial
(RCT) on 285 diabetic patients with gastroparesis, 10 or 14 mg
metoclopramide doses, administrated via nasal spray could not
reduce the overall symptom scores significantly more than pla-
cebo.72 However, when males and females were analyzed sepa-
rately, a significant effect was observed in females. Reported
adverse events were mainly headache, fatigue, and dysgeusia.
Domperidone is a peripherally acting dopamine‐2 antagonist that
decreases nausea and increases GE rates. It does not readily cross
the blood–brain barrier, making it much less likely to cause
extrapyramidal side effects. However, domperidone is associated
with prolongation of the cardiac QTc interval which has restricted
its use.73
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The 5‐HT3 antagonists, such as ondansetron or granisetron, also
have antiemetic properties, but controlled studies in gastroparesis
are lacking. An open label study suggested efficacy of granisetron
transdermal patches for controlling nausea and vomiting in gastro-
paresis.74 Aprepitant, a neurokinin‐1 receptor antagonist approved
for use for the treatment of chemotherapy‐induced emesis, was
efficacious in the treatment of nausea in some patients with gas-
troparesis and related disorders.75
Clinical trials of prokinetic agents report that, as a group, they
enhance symptoms and improve GE rate.76 However, there is
disparity, as the relationship between improvement of symptoms and
enhancement of GE rate is poor but becomes significant when only
high‐quality emptying studies are considered.76,77 The availability of
prokinetics is limited in many parts of the world, but new prokinetic
agents are in the pipeline for the treatment of gastroparesis.78
Nevertheless, GE rate enhancement per se cannot be used as a
marker of clinical efficacy.79 Based on these considerations, the panel
did not support efficacy of prokinetics as a treatment group. The
panel did support the classes of dopamine‐2 antagonists and 5‐HT4
agonists as having efficacy for treating gastroparesis symptoms.
Itopride, available in Asia and to some extent in Eastern Europe,
is a combined dopamine‐2 antagonist and cholinesterase inhibitor,
which has been extensively studied in FD. A small controlled cross‐
over study evaluating the effect of itopride 200 mg t. i.d. in 25
diabetic gastroparesis patients found no significant effect.80
Cisapride was for a long time the preferred medication for
outpatient treatment of gastroparesis but has been withdrawn from
the market because of cardiologic side effects.81 Tegaserod, another
5‐HT4 agonist, showed ability to enhance GE but was temporarily
withdrawn from the market and only developed for bowel disor-
ders.82 Prucalopride, a 5‐HT4 agonist belonging to another chemical
class, is approved in most countries for the treatment of chronic
constipation. In a recent study of mainly idiopathic gastroparesis
patients, prucalopride was efficacious in improving GE rate and
symptoms, while a second study in mainly diabetic gastroparesis
patients failed to show benefit.83,84
Several motilin‐receptor agonists have been studied as potential
treatment of gastroparesis over the past 20 years: Camicinal
(GSK962040), RaQualia (RQ‐00201864), Mitemcinal (GM‐611), and
so on.85 Nevertheless, further research, investigating these drugs in
RCTs, is needed. Macrolide antibiotics such as erythromycin, which
may also act on the motilin receptor, are clinically available and have
been studied.58,85–87 The use of antibiotics to increase gastric
motility includes risks and side effects, such as resistance or tachy-
phylaxis.85 Three Ghrelin‐receptor agonists, TZP‐101, TZP‐102, and
RM‐131 (relamorelin), have been studied in gastroparesis. Studies
with TZP‐101 and TZP‐102 showed inconsistent efficacy results in
diabetic gastroparesis.85 With regard to relamorelin, two random-
ized, placebo‐controlled trials, with a significant number of included
patients have been published.88,89 A phase 3 program in diabetic
gastroparesis was in progress but has recently been discontinued.
Neuromodulators are often used for managing refractory
symptoms in functional and motility disorders.90 The only
gastroparesis focused study was performed with nortriptyline in 130
idiopathic gastroparesis patients, showing no gain over placebo.91 A
second multicenter, randomized, double‐blind controlled study
compared amitriptyline 50 mg with escitalopram 10 mg in patients
with FD.92 Only amitriptyline appeared beneficial, particularly in
patients with ulcer‐like FD who were threefold more likely to report
symptom relief. When stratifying patients according to GE rate, no
beneficial effect was seen with amitriptyline or citalopram in this
subgroup.91 No studies with selective noradrenaline/serotonin re-
uptake blockers have been performed in patients with gastroparesis.
While there are controlled studies supporting the use of mirtazapine
and buspirone in FD, no controlled data are available for gastro-
paresis. A prospective, open label study of mirtazapine 15 mg in
gastroparesis patients demonstrated an improvement in symptoms of
nausea and vomiting and perceived loss of appetite.93
Uncontrolled long‐term cohort studies have reported efficacy
ofGES in patients with gastroparesis in terms of improving symptom
scores and quality of life.94–96 However, these results were not
further corroborated by RCTs.97–99 A recent sham‐controlled,
multicenter study from France reported improvement on vomiting
frequency, regardless of the GE status.100 Most of studies failed to
demonstrate acceleration of GE by GES, and the most recent study
demonstrates that delayed GE is not a prerequisite for the anti-
vomiting effect of GES.
Open‐label studies all reported short term (<6 months) efficacy
of intrapyloric injection of botulinum toxin both on symptoms and GE
in gastroparesis.101 However, two subsequent controlled trials failed
to demonstrate an improvement in symptoms and GE.102,103 Several
open‐label studies reported short and midterm (<18 months) efficacy
of endoscopic pyloric myotomy on symptoms, quality of life, and GE
in gastroparesis.104 However, there are currently no controlled
validating observational studies on the efficacy of pyloric myotomy.
In light of disappointing results from several RCTs evaluating intra-
pyloric injection of botulinum toxin, these open‐label observations
warrant further corroboration by RCTs. Whether the preassessment
of pyloric physiology in order to improve patient selection to intra-
pyloric injection of botulinum toxin and/or pyloric myotomy remains
uncertain.105 Only one report mentioned the occurrence of dumping
syndrome in two patients after laparoscopic pyloroplasty.106
Only a few studies in limited numbers of patients evaluated the
outcomes of near‐total gastrectomy with Roux‐en‐Y reconstruc-
tion107,108 or completion gastrectomy.109–113 Symptomatic
improvement was reported in 43%–90% of patients, mainly for
nausea, vomiting, or pain, but morbidity occurred in up to 40%.
Very limited data exist on the effect of H. pylori eradication in
gastroparesis. Two studies from China suggested that eradication
enhanced GE rate but they used nonvalidated GE tests.114,115 A
number of herbal therapies have been used for the treatment of FD,
including peppermint oil with or without caraway oil, ginger, Iber-
ogast, Rikkunshito, and Artichoke Extract.116 However, there is a lack
of data on their effects in gastroparesis. In a placebo‐controlled study
in 106 FD or gastroparesis patients, STW‐5 (Iberogast) did not alter
GE rate.117
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For hypnotherapy, cognitive behavioral therapy and mindfulness,
there is a lack of specific reports in gastroparesis patients. A few
Western and multiple Chinese studies have evaluated the efficacy of
acupuncture for diabetic or postoperative gastroparesis. A Cochrane
systematic review found overall higher symptom improvement rates
with acupuncture compared to usual or medical therapy, but due to
the heterogeneity and low quality of studies, and the risk of bias, the
conclusion is considered uncertain.118
Several algorithms propose nutritional support in the form of
enteral or parenteral nutrition for refractory gastroparesis with
weight loss and/or nutritional deficiencies.44,71,119 While short‐term
parenteral nutrition may provide rapid weight recovery, its long‐
term use should be avoided for risk of catheter‐related sepsis and
hepatotoxicity.119 Jejunal tube feeding has been advocated for long‐
term nutritional support in gastroparesis. Case series in diabetic
gastroparesis from the Mayo Clinic and idiopathic gastroparesis from
Leuven show that percutaneous feeding tube positioning is
associated with acceptable morbidity and mortality, allows weight
recovery, and that the jejunal tube can be removed after an average
period of 20 months.120,121
7. Prognosis of gastroparesis
7.1 The long‐term prognosis of gastroparesis is unfavorable in
the majority of patients.
STATEMENT NOT ENDORSED, overall agreement 35%: A+
15%, A 20%, A− 28%, D− 23%, D 15%, D+ 0%. GRADE B
7.2 The prognosis of gastroparesis depends on the cause.
STATEMENT ENDORSED, overall agreement 88%: A+ 33%,
A+ 54%, A 10%, A− 3%, D− 0%, D 0%, D+ 0%. GRADE B
7.3 Life expectancy in gastroparesis is shortened.
STATEMENT NOT ENDORSED, overall agreement 25%: A+
5%, A 20%, A− 35%, D− 18%, D 23%, D+ 0%. GRADE B
The natural history and outcome of patients with gastroparesis is
incompletely understood. Cohort studies from tertiary care centers
suggest that symptoms and GE delay persist for several years in the
majority of patients.123–125 In a 262 patient follow‐up cohort from
the NIDDK gastroparesis consortium, there was some symptom
improvement of symptoms at 48 weeks, but not from 48 to 192
weeks. Factors independently associated with reduced symptoms at
48 weeks included male sex, age above 50, an initial infectious pro-
drome, antidepressant use, and a 4‐h gastric retention more than
20%. Factors associated with lack of improvement of symptoms
included overweight or obesity, a history of smoking, the use of pain
modulators, moderate to severe abdominal pain, severe gastro-
esophageal reflex, and moderate to severe depression.122 Case series
have also reported a higher likelihood of symptom resolution or
improvement in patients with a presumed post‐infectious form of
gastroparesis.17,26
In terms of the effect of gastroparesis on life expectancy, data
are conflicting. Based on 86 diabetic patients who were followed
for at least 9 years, delayed GE was not related with mortality
after adjustment for comorbidities,125 but 6‐year follow‐up data
from a tertiary care setting observed that 7% had died and 22%
needed long‐term parenteral or enteral feeding, suggesting gas-
troparesis is not a benign condition.124 Studies conducted in
referral populations demonstrate no effect of delayed GE on
mortality among patients with diabetes mellitus after 12–25 years
of follow‐up.126,127 In the analysis of the UK CPRD database,
mortality risk was higher in diabetic compared to idiopathic gas-
troparesis patients (adjusted hazard ratio: 1.9, 95% CI: 1.2–3.0).24
A population‐based study compared the observed and expected
mortality of patients with gastroparesis, demonstrating a signifi-
cantly higher death rate in patients compared to age‐and sex‐
matched controls, which was largely due to cardiovascular co-
morbidity in diabetic patients.23
RECOMMENDATIONS
Based on the statements that achieved consensus, a number of rec-
ommendations for understanding and managing of gastroparesis can
be made (Table 3), which are summarized in Table 4 and Figure 1. The
Delphi process also identified several areas of uncertainty, which
require additional evidence or further research.
In line with existing definitions and guidelines, gastroparesis is
based on the presence of upper gastrointestinal symptoms and
delayed GE in the absence of an obstructive lesion.1–4 The panel also
agrees that gastroparesis is associated with other manifestations of
severely disturbed gastric motor function.12–14 The European
consensus identifies nausea and vomiting as the cardinal symptoms
of gastroparesis. While the panel also agrees that there are often
coexisting FD/PDS symptoms, the presence of predominant nausea
and vomiting offers an approach to differentiate (idiopathic) gastro-
paresis from PDS, where early satiation or postprandial fullness are
dominant symptoms.2,4,18,19 The overlap with EPS is considered less
prevalent.4,17,20
There is consensus that the true epidemiology of gastroparesis is
not known, but that diabetes, gastric surgery, certain neurological
and connective tissue diseases, as well as the use of certain drugs are
associated with an increased risk of gastroparesis.23–25,29–34 The
panel agreed that gastroparesis has an important impact on quality of
life and healthcare costs, and also concurs that gastroparesis is often
associated with psychological comorbidities such as anxiety and
depression.35,40–42 There is no consensus that gastroparesis may lead
to unintended weight loss, but when present, eating disorders must
be excluded.9,43–45
In terms of pathophysiological mechanisms that are relevant to
gastroparesis, while the panel agreed that severely impaired gastric
motor function is present in these patients, there was no consensus
for a direct role for delayed emptying, impaired gastric accommo-
dation or gastric hypersensitivity in determining symptom pattern
and severity.1–4,8–13,16,17,20,21,32 There was also no qualifying majority
support for pivotal pathophysiological roles for loss of interstitial
cells of Cajal, intrinsic or extrinsic (vagus) nerves, changes in smooth
muscle, peptide hormone release, gastric acid secretion, duodenal
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1.1. Gastroparesis refers to a symptom or set of symptoms that is(are) associated with
delayed gastric emptying in the absence of mechanical obstruction
Yes A 1–4
1.2. Gastroparesis refers to a symptom or set of symptoms that is(are) associated with
severely disturbed gastric motor function in the absence of mechanical obstruction
Yes B 1–4
1.3. Nausea and vomiting are cardinal symptoms in gastroparesis Yes B 4, 9, 10, 16–19
1.4. Dyspeptic symptoms such as postprandial fullness, early satiation, epigastric pain, as
well as bloating in the upper abdomen and belching are often present in gastroparesis
patients
Yes B 4, 9, 12
1.5. Symptoms in gastroparesis patients overlap mainly with PDS and less with EPS
symptoms of FD
Yes B 12, 17, 20
2.1. The epidemiology of gastroparesis is not established, mainly because it requires gastric
emptying testing which has not been done at the population level
Yes B 23, 24
2.2. Diabetes is a risk factor for development of gastroparesis Yes A 23–25
2.3. Acute gastrointestinal infection is a risk factor for development of gastroparesis No B 26–28
2.4. Partial gastric resection/vagotomy, bariatric surgery, antireflux surgery are risk factors
for development of gastroparesis
Yes B 29, 30
2.5. Hypothyroidism is a risk factor for development of gastroparesis No C 31
2.6. Some neurological disorders (e.g., Parkinson's disease, multiple sclerosis, amyloid
neuropathy) are associated with increased risk for gastroparesis
Yes B 23, 31–33
2.7. Some connective tissue diseases are associated with increased risk for gastroparesis Yes B 23, 31–33
2.8. Some drugs (e.g., opioids) are associated with increased risk for gastroparesis Yes A 1, 4, 21, 34
3.1. Gastroparesis is a major source of healthcare costs Yes A 35, 36
3.2. Gastroparesis is associated with decreased life expectancy No 35, 36
3.3. Gastroparesis is a major source of self‐costs to patients No B 35, 36
3.4. Gastroparesis is an important source of loss of work productivity No B 37–39
3.5. Gastroparesis is associated with a significant decrease in quality of life Yes A 40
3.6. Gastroparesis is associated with psychosocial co‐morbidities such as anxiety and
depression
Yes A 41, 42
3.7. Weight loss can be consequence of gastroparesis No B 9, 42
3.8. In case of weight loss, eating disorders must be ruled out Yes B 44, 45
3.9. Healthcare consulting behavior in gastroparesis is driven by symptom severity and
impact
No B 41, 46
3.10. Healthcare consulting behavior in gastroparesis is driven by psychosocial co‐
morbidity
No B 41, 46
3.11. Healthcare consulting behavior in gastroparesis is driven by access to the healthcare
system
No B 41, 46
4.1. Delay in gastric emptying underlies symptom generation in gastroparesis No B 1–4, 8–13, 16, 17,
20, 21, 32
4.2. Impaired gastric accommodation contributes to symptom generation in gastroparesis No B 12, 13
4.3. Hypersensitivity to gastric distention contributes to symptom generation in
gastroparesis
No B 12, 13
4.4. Duodenal mucosal alterations (low grade inflammation, impaired permeability) are not
implicated as pathophysiological mechanisms in gastroparesis
No C 47
4.5. Loss of interstitial cells of Cajal is a pathophysiological mechanism in gastroparesis No B 48–51
4.6. Loss of enteric nerves is a pathophysiological mechanism in gastroparesis Yes B 48–51
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4.7. Primary changes in gastric smooth muscle are a pathophysiological mechanism in
gastroparesis
No B 48–52
4.8. Loss of vagus nerve function is a pathophysiological mechanism in gastroparesis No B 53, 55
4.9. HP infection is not a pathophysiological mechanism in gastroparesis No B 55–57
4.10. Altered gastric acid secretion is not a pathophysiological mechanism in gastroparesis No C 1–4
4.11. Altered release of peptide hormones is not a pathophysiological mechanism in
gastroparesis
No C 58
4.12. Increased sensitivity to duodenal luminal content is not a pathophysiological
mechanism in gastroparesis
No C 47
4.13. Altered duodenal microbiota composition is not a pathophysiological mechanism in
gastroparesis
No C 47
4.14. Anxiety is a pathophysiological factor in gastroparesis No B 34–49
4.15. Depression is a pathophysiological factor in gastroparesis No B 34–49
4.16. Disordered processing of incoming signals from the gastroduodenal region is a
pathophysiological mechanism in gastroparesis
No B 59, 60
4.17. Genetic factors determine susceptibility to gastroparesis No C 61
5.1. Upper GI endoscopy is mandatory for establishing a diagnosis of gastroparesis Yes A 1, 2, 19
5.2. The presence of food in fasting state during endoscopy is diagnostic for gastroparesis No B 23, 62
5.3. An abnormal gastric emptying test is mandatory for establishing a diagnosis of
gastroparesis
Yes A 1–4, 63–67
5.4. Scintigraphic gastric emptying assessment is a valid test for diagnosing gastroparesis Yes A 63, 64
5.5. Breath test assessment is a valid test for diagnosing gastroparesis Yes A 65
5.6. Wireless motility capsule assessment is a valid test for diagnosing gastroparesis No B 66
5.7. Gastric ultrasound assessment is a valid test for diagnosing gastroparesis No B 66, 67
5.8. Small bowel obstruction can be ruled out in gastroparesis through imaging Yes B 68
6.1. Dietary adjustments are useful for managing gastroparesis patients No B 17, 69
6.2. Proton pump inhibitor (PPI) therapy is the most appropriate first line therapy for
gastroparesis
No C 17, 70
6.3. PPI therapy is effective in gastroparesis No C 17, 70
6.4. PPI therapy is only effective for associated reflux symptoms in gastroparesis No C 17, 70
6.5. Anti‐emetic (anti‐“nauseant”) therapy is the most appropriate first line therapy for
gastroparesis
No B 71
6.6. Antiemetic (anti‐“nauseant”) therapy is effective for gastroparesis No B 71
6.7. Dopamine‐2 antagonists are effective for gastroparesis Yes B 71–73
6.8. 5‐HT3 antagonists are effective for gastroparesis No B 74
6.9. NK1 antagonists are effective for gastroparesis No B 75
6.10. Prokinetic therapy is the most appropriate first line therapy for gastroparesis No B 76–79
6.11. Prokinetic therapy is effective for gastroparesis No B 76–79
6.12. The efficacy of prokinetics is not related to their enhancement of gastric emptying
rate
No B 76–79
6.13. Itopride is effective for gastroparesis No B 80
6.14. 5‐HT4 agonists are effective for gastroparesis Yes B 81–84
(Continues)
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mucosal changes, psychosocial comorbidity, or altered central pro-
cessing in the generation of gastroparesis symptoms.47–70
There is consensus that an abnormal GE test as well as an EGD,
to rule out mechanical obstruction, are mandatory for establishing a
diagnosis of gastroparesis, but that the presence of food at endos-
copy is not a reliable diagnostic marker.1,2,19,23,62 Radiological ex-
aminations, preferably using a CT scan, can be added in case of
uncertainty regarding the absence of a mechanical obstructive factor.
Scintigraphy and breath tests are agreed to be reliable diagnostic
tests, but there is no support for the WMC or gastric ultrasound to
detect delayed GE.63–67
Besides the statements on pathophysiology, the section on
treatment approaches is a second one to display a major lack of
consensus. In spite of very few literature data,69 the panel supported
dietary intervention in the treatment of gastroparesis. There is no
consensus on the efficacy of PPIs, nor for different types of anti-
emetics.70–75 There is borderline support (78% agreement) for the
use of prokinetics as a group, but the panel agreed on the use of
5‐HT4 receptor agonists as a class.76–89 There is also no consensus on
the use of other neuromodulators, herbal therapies, acupuncture or
psychological therapies in gastroparesis.90–93,116–118 The same is true
for invasive therapies such as botulinum toxin injection, GES, pyloric




6.15. Motilin‐receptor agonists are effective for gastroparesis No B 85–87
6.16. Ghrelin‐receptor agonists are effective for gastroparesis No B 88, 89
6.17. Tricyclic antidepressants are effective for gastroparesis No B 90–92
6.18. Tricyclic antidepressants are not effective for gastroparesis No B 90–92
6.19. SSRI are effective for gastroparesis No C 90, 92
6.20. SSRI are not effective for gastroparesis No C 90, 92
6.21. SNRI are effective for gastroparesis No C 90
6.22. SNRI are not effective for gastroparesis No C 90
6.23. Mirtazapine is effective for gastroparesis No B 90, 93
6.24. 5‐HT1A agonists (tandospirone, buspirone, ….) are effective for gastroparesis No C 90
6.25. 5‐HT1A agonists are not effective for gastroparesis No C 90
6.26. Gastric electrical stimulation is effective for gastroparesis No B 94–100
6.27. Pyloric botulinum toxin injection is effective for gastroparesis No B 101–103
6.28. Pyloric myotomy is effective for gastroparesis No B 104, 105
6.29. Partial or subtotal gastrectomy is effective for gastroparesis No B 107–113
6.30. Surgical or pyloric targeting therapies for gastroparesis may induce dumping
syndrome
No B 106
6.31. Helicobacter pylori‐infected gastroparesis patients should receive eradication therapy No B 114, 115
6.32. Herbal therapies are effective for gastroparesis. No B 116
6.33. Herbal therapies are not effective for gastroparesis No B 116
6.34. Iberogast (STW‐5) is effective for gastroparesis No B 117
6.35. Hypnotherapy is effective for gastroparesis No B 117
6.36. Cognitive behavioral therapy is effective for gastroparesis No B 118
6.37. Acupuncture is effective for gastroparesis No B 118
6.38. Mindfulness is effective for gastroparesis No B 118
6.39. In case of severe weight loss or intractable vomiting, nutritional support may be
needed in the form of enteral or parenteral nutrition
Yes B 44, 71, 119–121
7.1. The long‐term prognosis of gastroparesis is unfavorable in the majority of patients No B 24, 123–126
7.2. The prognosis of gastroparesis depends on the cause Yes B 24, 123–126
7.3. Life expectancy in gastroparesis is shortened No B 24, 123–128
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endoscopic myotomy or (partial) gastrectomy.95–113 There is agree-
ment on the use of nutritional support in case of severe weight
loss.44,71,119–121 Finally, there is consensus that the long‐term
prognosis of gastroparesis depends on the cause, but there is no
consensus on an unfavorable long‐term prognosis or increased
mortality.123–128
TAB L E 4 Summary of the ESNM consensus on gastroparesis
Recommendations Based on statement(s)
Gastroparesis refers to a symptom or set of symptoms that is (are) associated with delayed gastric emptying in the
absence of mechanical obstruction, as well as severely disturbed gastric motor function
1.1, 1.2
Nausea and vomiting are the cardinal symptoms of gastroparesis. Symptoms in gastroparesis patients overlap mainly
with postprandial distress syndrome symptoms such as postprandial fullness, early satiation, epigastric pain, as well
as bloating in the upper abdomen
1.3, 1.4, 1.5
The epidemiology of gastroparesis is not established, mainly because it requires gastric emptying testing which has not
been done at the population level
2.1
Diabetes, upper abdominal surgeries, neurological and connective tissue diseases as well as the use of certain drugs are
risk factors for development of gastroparesis
2.3, 2.4, 2.6, 2.7, 2.8
Gastroparesis is a major source of healthcare costs 3.1,
Gastroparesis is associated with a significant decrease in quality of life and with psychosocial co‐morbidities 3.5,3.6
In case of weight loss, an eating disorder must be ruled out 3.8
Upper GI endoscopy to rule out mechanical obstruction and an abnormal gastric emptying test are mandatory for
establishing a diagnosis of gastroparesis. Gastric emptying can reliably be assessed by scintigraphy or breath test.
Additional radiological imaging can be used to exclude obstruction in case of doubt
5.1, 5.3, 5.4, 5.5, 5.8
Gastroparesis patients should be explained dietary adjustments. Dopamine‐2 antagonists or 5‐HT4 agonists can be
used to manage symptoms
6.1, 6.7, 6.14
In case of severe weight loss in gastroparesis, nutritional support may be needed 6.39
The long‐term prognosis of gastroparesis depends on the underlying cause 7.2
Abbreviation: ESNM, European Society for Neurogastroenterology and Motility.
F I GUR E 1 Schematic representation, in an algorithm‐like fashion, of the outcome of the ESNM consensus on gastroparesis management.
The blue arrows depict the diagnostic and therapeutic flow of the patient. Green arrows refer to risk or pathophysiological factors. The circles
depict the percentage of agreement, using a green color for ≥80% consensus, light orange for consensus between 70% and 80%, and dark
orange for lower levels of consensus. ESNM, European Society for Neurogastroenterology and Motility
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The most important progress with this consensus is the identifica-
tion of a cardinal symptom pattern for gastroparesis: nausea or vomit-
ing, with or without overlapping PDS. In the past, the separation of
gastroparesisfromFDhasbeenanissueofcontroversy,andnovelterms
suchas (diabetic) gastropathyandFDwithdelayedemptyinghavebeen
proposed.128,129 The same Delphi panel for the current consensus also
generated the ESNM FD guideline, confirming early satiation, post-
prandial fullness and epigastric pain or burning as cardinal FD symp-
toms.6 These different cardinal symptom‐based approachesmay allow
for abetterdifferentiationof gastroparesis fromFDfor future research
and clinical management. Otherwise, the areas of uncertainty revealed
by this consensus are multiple. There is no consensus and hence no
clarity on the underlying pathophysiological factors in gastroparesis.
The therapy section also sees little agreement, as only dietary therapy
and 5‐HT4 receptor agonists are considered appropriate by consensus,
even though the available evidence is limited. It is anticipated that ad-
vances in our understanding of pathophysiology of FD and gastro-
paresis,andhowsymptomsaregeneratedintheseconditions,mayallow
refinement of definitions and identifications of more specific pheno-
types with definable treatment response. Moreover, this clearly es-
tablishes the need formore therapeutic trials to determine the place of
anti‐emetics, other classes of prokinetics, neuromodulators and
perhaps even PPIs. For now, the path to regulatory approval for gas-
troparesis treatments remainsunfinished.Forsomeof theolderagents,
scientific or professional organizations such as ESNM or the Rome
Foundation may consider taking the lead.
CONCLUSION
This Delphi process used a multinational and multidisciplinary group
of European experts to summarize the current state of consensus on
definition, symptom characteristics, pathophysiology, diagnosis,
treatment, and prognosis of gastroparesis. The Consensus Group
voted on several statements that may guide clinicians in recognizing,
diagnosing and treating gastroparesis in clinical practice, whereas the
statements without consensus identify areas in need of future
research.
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